Stay updated on Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a new version, changing from Revision v2.16.6 to v2.16.8, and it now includes information about HHS Vulnerability Disclosure.
    Difference
    0.2%
    Check dated 2025-07-25T15:17:04.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.5 to version 2.16.6.
    Difference
    0.1%
    Check dated 2025-07-18T12:04:17.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A service alert has been added regarding planned maintenance starting July 25th, during which most services will be unavailable for over 24 hours.
    Difference
    0.9%
    Check dated 2025-07-11T07:30:59.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version and a change in the status of a clinical trial, now listed as 'unknown status'.
    Difference
    2%
    Check dated 2025-07-04T04:17:24.000Z thumbnail image
  5. Check
    41 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.8%
    Check dated 2025-06-19T20:00:45.000Z thumbnail image
  6. Check
    55 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.1%
    Check dated 2025-06-05T11:22:42.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Fulvestrant in HR+ HER2- Breast Cancer Clinical Trial page.